Introduction {#sec1}
============

Molecular oxygen (O~2~) is required for aerobic metabolism to maintain intracellular bioenergetics and serves as an electron acceptor in many biochemical reactions.^[@ref1]^ Ambient air contains 21% of O~2~; however, most mammalian tissues exist at 2--9% O~2~. Hypoxia, usually defined as ≤2% O~2~, occurs in a variety of pathological conditions, including stroke, tissue ischemia, inflammation, and tumor growth.^[@ref2]^ Cells have developed a number of essential mechanisms to cope with the stress of hypoxia. Among these coping mechanisms is the response mediated by the hypoxia-inducible factor 1 (HIF-1).^[@ref3]^

HIF-1 is a basic helix--loop--helix PER-ARNT-SIM (bHLH-PAS) family protein that forms a heterodimer with its α and β subunits and functions as a transcription factor.^[@ref4]^ While HIF-1β is constitutively active, HIF-1α is regulated by oxygen status. In well-oxygenated states, constitutively synthesized HIF-1α undergoes continuous degradation.^[@ref5]^ During this process, two proline sites (Pro402 and Pro564) in the oxygen-dependent degradation (ODD) domain are hydroxylated by prolyl hydroxylase.^[@ref6]^ Of the three prolyl hydroxylases (PHD1, PHD2, and PHD3) identified in mammalian cells, PHD2 is known to play a major role. Under normoxic conditions, PHD2 uses molecular oxygen and 2-oxoglutarate (α-ketoglutarate) as cosubstrates for proline hydroxylation of HIF-1α. Hydroxylated HIF-1α is then recognized by the tumor suppressor protein von Hippel--Lindau (VHL), subsequently ubiquitinated, and degraded. Hypoxic O~2~ levels limit the ability of PHD2 to function and result in enhanced stability of HIF-1α. Stabilized HIF-1α forms a heterodimer with its β subunit and translocates into the nucleus where it binds to its target gene promoters known as hypoxia response elements (HREs) and activates gene transcription. HIF-1 is a main regulator of hypoxia, activating several hundred genes involved in angiogenesis (VEGF), glucose transport (GLUT1), glycolytic pathways (LDH-A), ROS signals (iNOS), erythropoiesis (EPO), and a variety of other processes.^[@ref7]^

Tumors adapt to hypoxia by increasing angiogenesis and metastatic potential, altering apoptosis, and regulating metabolism.^[@ref8]^ These adaptations mediated by HIF-1 make tumors both more aggressive and treatment-resistant, resulting in poor clinical outcomes.^[@ref9]−[@ref11]^ Immunohistochemical analyses have revealed that HIF-1α is overexpressed in many human cancers and is closely associated with patient mortality.^[@ref12]^ HIF-1 overexpression is not only involved in tumor progression but also associated with resistance to radiation and chemotherapy.^[@ref13]−[@ref15]^ Due to the importance of HIF-1 in tumor development and progression, a considerable amount of effort has been made to identify HIF-1 inhibitors for treatment of cancer.^[@ref16]−[@ref20]^

*Saururus cernuus* L. (Saururaceae), an aquatic plant found throughout the eastern half of the United States, has a long history of medicinal use in the treatment of tumors by both native Americans and early colonists. The dineolignans manassantin A (**1**), manassantin B (**2**), 4-*O*-demethylmanassantin B (**3**), and manassantin B~1~ (**4**) are natural products isolated from *Saururus cernuus* ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}).^[@ref21]−[@ref23]^ Manassantins (**1**--**4**) have been shown to be HIF-1 inhibitors *in vitro*.^[@ref22]−[@ref24]^

![Structure of dineolignans from *Saururus cernuus*.](jm-2015-01220f_0001){#fig1}

In broad connection with our interest in using natural products to understand the signaling pathways in biology,^[@ref25]−[@ref28]^ we devised a convergent synthetic route to **1** and **2** that would be easily amenable to the synthesis of analogues for biological studies.^[@ref24]^ After completing the synthesis of **1** and **2**, we determined the effect of these manassantins on HIF-1 and VEGF expression.^[@ref24],[@ref29]^ These studies revealed that manassantin A (**1**) is a potent inhibitor of HIF-1 activity. Western blots of 4T1 cells (murine mammary carcinoma cells) exposed to **1** under hypoxic conditions showed that hypoxia-induced HIF-1α expression was significantly inhibited at concentrations between 10 and 100 nM. Furthermore, HIF-1 regulated VEGF secretion was dramatically reduced by **1**. Evaluation of **1** in the National Cancer Institute's 60-cell line screen^[@ref30]^ showed that **1** possesses strong differential cytotoxicities against several breast, leukemia, and melanoma cell lines (see the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5b01220/suppl_file/jm5b01220_si_001.pdf) for details).

Encouraged by the potential of manassantins as novel therapeutics for cancer, we prepared a series of manassantin analogues to define the structural requirements for HIF-1 inhibition. Herein, we describe our efforts toward the synthesis and SAR study of manassantin analogues to guide the design of structurally simplified manassantins for anticancer therapeutic development.

Results and Discussion {#sec2}
======================

Chemistry {#sec2.1}
---------

Manassantins A (**1**) and B (**2**) consist of two regions ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}): a tetrahydrofuran core region and a side chain region. Since we demonstrated that the 2,3-*cis*-3,4-*trans*-4,5-*cis*-configuration of the tetrahydrofuran core is critical for HIF-1 inhibition,^[@ref29]^ we envisioned the preparation of a series of analogues with modification of the substituents and the length of the side chains in an effort to establish a more comprehensive SAR and identify manassantin analogues with reduced structural complexity. The manassantin analogues could be easily prepared from the known tetrahydrofuran core **5**([@ref24]) following the convergent synthetic approach shown in [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}. We anticipated that SAR studies would identify structural motifs and minimal structural requirements required for HIF-1 inhibition. Such information will allow structural modifications to increase specificity, decrease off-target effects, and improve drug performance.

![A convergent synthetic approach to manassantin analogues.](jm-2015-01220f_0002){#fig2}

First, we prepared an extended side chain analogue (**MA02**) to gain insights into the importance of side chain length in HIF-1 inhibition. The synthesis of **MA02** started with the preparation of tosylate **10** and α-bromoketone **12** for coupling reactions ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}). Benzyl (Bn)-protection of the known *trans*-*m*-propenyl guaiacol (**6**)^[@ref31]^ followed by asymmetric dihydroxylation^[@ref32]^ of **7** provided diol **8**. Selective DDQ-oxidation of the benzylic hydroxyl group of **9** followed by tosylation successfully afforded **10**. α-Bromoketone **12** was prepared by treatment of the commercially available 3′,4′-dimethyoxyacetophenone (**11**) with Br~2~.^[@ref33]^ BEMP-mediated coupling of tetrahydrofuran core **5**([@ref24]) and tosylate **10** and Bn-deprotection provided **MA01** in excellent overall yield. Final coupling of **MA01** with **12** completed the synthesis of **MA02**.

![Synthesis of Extended Analogue (**MA02**)](jm-2015-01220f_0003){#sch1}

As shown in [Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}, a truncated analogue (**MA03**) was prepared by monoalkylation of **5** with the known tosylate **14**([@ref24]) (48%) followed by methylation (K~2~CO~3~, MeI, 93%). Stereoselective reduction of **MA03** with polymer-bound BH~4~ afforded the desired truncated analogue (**MA04**, 4-*O-*methylsaucerneol)^[@ref23]^ in 80% yield, which constitutes the first synthesis of 4-*O-*methylsaucerneol.

![Synthesis of Truncated Analogues (**MA03** and **MA04**)](jm-2015-01220f_0004){#sch2}

We hypothesized that the C7 and C7‴ hydroxyl groups could play an important role by providing hydrogen bonds to the binding target(s) or influencing the conformation of the side chains via intramolecular hydrogen bonds with the neighboring ether oxygen atom. To test this hypothesis, we synthesized the corresponding keto analogue (**MA05**)^[@ref24]^ by coupling **5** and **14**. The C7/C7‴ methoxy analogue (**MA06**) was prepared by methylation of manassantin A (**1**) with NaH and MeI (79%) ([Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"}).

![Synthesis of C7/C7‴ Keto and Methoxy Analogues (**MA05** and **MA06**)](jm-2015-01220f_0005){#sch3}

To define the role of C8/C8‴ methyl groups and reduce the structural complexity of manassantin side chains, we prepared C8/C8‴ desmethyl analogues (**MA07**--**MA09**) and C8/C8‴ desmethyl and C7/C7‴ deoxo analogue (**MA10**) ([Scheme [4](#sch4){ref-type="scheme"}](#sch4){ref-type="scheme"}). Alkylation of tetrahydrofuran core **5** with α-bromoketone **12** provided **MA07** in modest yield. Asymmetric Corey--Bakshi--Shibata reduction^[@ref34]^ of **MA07** afforded **MA08** as a single diastereomer (82%), which was further converted to **MA09** by methylation with NaH and MeI. To further reduce the complexity of manassantins, we removed both C8/C8‴ methyl and C7/C7‴ hydroxyl groups and prepared **MA10** by coupling **5** with the commercially available 4-(2-bromoethyl)-veratrole (**16**). In addition to reducing the structural complexity, removal of the benzylic hydroxyl groups would reduce the number of hydrogen-bonding donors and influence PK/PD parameters by improving permeability and absorption and removing the potential metabolism site (e.g., phase-2 conjugation).^[@ref35]^

![Synthesis of C8/C8‴ Desmethyl and C7/C7‴ Deoxo Analogues (**MA07**--**MA10**)](jm-2015-01220f_0006){#sch4}

Previously, it was reported that a reduction in potency was observed with the replacement of the C4 methoxy group in the distal phenyl rings of manassantins A (**1**, [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}) and B (**2**) with a hydroxyl group as in 4-*O*-demethylmanassantin B (**3**).^[@ref23]^ To characterize the role of the methoxy groups on the distal phenyl rings, we prepared the C3/C3‴ hydroxy analogue (**MA01**) (the intermediate to **MA02**, [Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}) and phenyl analogues (**MA11** and **MA12**) ([Scheme [5](#sch5){ref-type="scheme"}](#sch5){ref-type="scheme"}). Asymmetric dihydroxylation of the commercially available (*E*)-1-propenyl-benzene (**17**) provided diol **18** in 92% yield. Selective DDQ-oxidation of the benzylic hydroxyl group of **18** followed by tosylation smoothly proceeded to afford tosylate **20**. BEMP-mediated coupling of **5** with **20** successfully provided **MA11**, which was reduced stereoselectively to give **MA12**.

![Synthesis of Phenyl Analogues (**MA11** and **MA12**)](jm-2015-01220f_0007){#sch5}

Biological Characterization {#sec2.2}
---------------------------

After the completion of the analogue synthesis, we performed a dual luciferase-reporter assay to assess the effect of manassantin analogues (**MA01**--**MA12**) on HIF-1 activity. We used HEK-293T cells (human embryonic kidney cells) transiently transfected with both pGL3-5HRE-Luc (pGL3-HRE-Luc) and pRL-SV40 encoding *Renilla* luciferase (pRen-Luc) vectors to investigate the effect of **MA01**--**MA12** on HIF-1 transactivation activity. We generated a reporter vector, pGL3-HRE-luciferase plasmid containing five copies of HRE sequences identical to that in the human VEGF promoter gene. The dual luciferase-reporter assay was used as an initial *in vitro* test to identify active compounds for further evaluation. HEK-293T cells were seeded in a 96-well plate at a density of 5 × 10^3^ cells/well. After 24 h incubation, cells were treated with hypoxic conditions (1% O~2~) and serially diluted compounds (**1** and **MA01**--**MA12**) for 24 h. To measure the firefly luminescence signals, Dual-Glo reagent was added, and the luminescence signals were measured by using a dual-color luminescence detection system. The luciferase signals were normalized to the activity of *Renilla* luciferase and quantified as relative light units (RLU) (see the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5b01220/suppl_file/jm5b01220_si_001.pdf) for details).

None of the analogues tested was as potent as manassantin A (**1**), but several manassantin analogues reduced the luciferase signal to the maximum percent inhibition level relative to that observed under normoxic conditions ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). The luciferase assay provided several valuable insights into SAR. First, the extended analogue **MA02** was almost inactive, suggesting the importance of the side chain length of manassantins in HIF-1 inhibitory activity. The truncated analogue **MA04** (4-*O-*methylsaucerneol), although less potent than **1**, still showed strong inhibition of HIF-1 activity (IC~50~ = 0.32 μM). Previously, Zhou and co-workers reported that **MA04** is less potent than **1** due to the absence of one side chain phenylpropyl unit,^[@ref23]^ which was further confirmed by our study. Although **MA04** possesses lower potency relative to **1**, the reduced molecular weight, hydrophobicity, and structural complexity obtained by removing one of the two side chains of **1** may allow for improvement of other crucial parameters in drug discovery (see the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5b01220/suppl_file/jm5b01220_si_001.pdf) for details).^[@ref35]^ Ligand efficiency (LE) has been utilized as a method for improving the overall performance of molecules by providing an index of how effectively a molecule uses its structural features to bind and inhibit its target.^[@ref36],[@ref37]^ Ligand efficiency indices compare molecules according to their average binding energy per atom or potency of inhibition per atom. This concept has been extended to include other properties such as lipophilicity, molecular mass, and polar surface area. These measures are typically focused on *in vitro* binding affinity and not on *in vivo* properties. Since overemphasis on potency can often produce large molecules with poor drug properties, optimizing ligand efficiency can be a very important metric in lead optimization. When the LE and physicochemical properties of **MA04** were calculated using the activity in our dual luciferase-reporter assay (see the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5b01220/suppl_file/jm5b01220_si_001.pdf) for details), **MA04** showed better ligand efficiency index (LEI, **MA04** = 0.16 vs **1** = 0.15) and binding efficiency index (BEI, **MA04** = 11.74 vs **1** = 10.84) than **1**. Moreover, **MA04** compared more favorably than **1** in other physicochemical property assessments (e.g., cLogP, number of rotatable bonds). Although multiple parameters (e.g., cell permeability) can impact cellular activity such that theoretical considerations of LE may not be directly applicable, the potency of **MA04** is significant given the improvement in many other parameters associated with good drug properties.

###### Chemical Structures and IC~50~ Values of **MA01**--**MA12** in Dual Luciferase-Reporter Assay

![](jm-2015-01220f_0009){#fx1}

  compound                IC~50~[a](#t1fn1){ref-type="table-fn"} (μM)   maximum percent inhibition relative to normoxia[a](#t1fn1){ref-type="table-fn"} (%)
  ----------------------- --------------------------------------------- -------------------------------------------------------------------------------------
  manassantin A (**1**)   0.011 ± 0.003                                 103 ± 11
  **MA01**                2.11 ± 0.66                                   78 ± 6
  **MA02**                \>10,000                                      36 ± 12
  **MA03**                3.70 ± 0.37                                   82 ± 6
  **MA04**                0.32 ± 0.10                                   113 ± 1
  **MA05**                0.91 ± 0.27                                   114 ± 5
  **MA06**                0.43 ± 0.14                                   102 ± 12
  **MA07**                0.35 ± 0.05                                   93 ± 10
  **MA08**                0.38 ± 0.10                                   94 ± 4
  **MA09**                1.93 ± 0.70                                   87 ± 8
  **MA10**                1.44 ± 0.62                                   64 ± 7
  **MA11**                0.69 ± 0.39                                   101 ± 18
  **MA12**                0.59 ± 0.12                                   79 ± 5

Data are mean values of three independent experiments. Errors represent standard deviation.

Analogues with the C7/C7‴ keto groups (**MA03** and **MA05**) showed lower activities than analogues with hydroxyl groups at the same positions (**MA03** vs **MA04**, **MA05** vs **1**), suggesting that the C7/C7‴ hydroxyl groups are important to the potency of **1**. Methylation of the C7/C7‴ hydroxyl groups (**MA06** and **MA09**) also reduced the potency (**MA06** vs **1**, **MA09** vs **MA08**). Removal of the C9/C9‴ methyl groups lowered the activity of the analogues (**MA08** vs **1**, **MA09** vs **MA06**), although in the C7/C7‴ keto analogues, **MA07** demonstrated good activity (IC~50~ = 0.35 μM) compared with **MA05** (IC~50~ = 0.91 μM). The lack of the C9/C9‴ methyl groups and displacement of the C7/C7‴ hydroxyl groups with keto groups in the structure of **MA07** dramatically simplifies the chemistry. Analogues (**MA11** and **MA12**) without the methoxy groups in the distal phenyl rings were significantly less potent than **1**, however, they showed IC~50~ values in the submicromolar range. Given that methoxy groups in a phenyl ring can be metabolically labile,^[@ref38]^ this result is noteworthy because it provides SAR information to guide optimization of PK parameters and to help design affinity probes for target identification studies.

One of the most critical aspects of drug discovery programs driven by natural products is the identification of structurally simple and synthetically more accessible compounds,^[@ref39]^ which ultimately aids the preparation of compounds in large quantities for preclinical and clinical studies. None of the analogues that we prepared and tested was as potent as **1**, but several analogues with reduced structural complexity such as **MA04** warrant further biological evaluations in this regard.

General toxicity of manassantin analogues was examined using the MTT assay, a standard colorimetric cytotoxicity assay. HEK-293T cells were seeded in a 96-well plate and treated with serially diluted **1** and **MA01**--**MA12** (0.005--10 μM) for 24 h under hypoxia. After 24 h treatment, MTT was added following manufacturer's protocol. The absorbance of the formazan was detected at 540 nm. Up to the highest concentration examined (10 μM), cells had \>80% survival rate in HEK-293T (see the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5b01220/suppl_file/jm5b01220_si_001.pdf) for details).

Following the initial dual luciferase-reporter assay, we used Western blots to further examine the down-regulation of HIF-1α by manassantin analogues. We selected a subset of manassantin analogues (**MA04**, **MA07**, and **MA11**) based on their potency (from luciferase-reporter assay), lack of general toxicity (from MTT assay), and structural simplicity. After incubating HEK-293T cells under hypoxia (1% O~2~) for 24 h with or without compounds, total protein lysate was extracted. Western blots were performed following the standard procedures. Compounds **MA04**, **MA07**, and **MA11** at 1 μM significantly down-regulated the expression level of HIF-1α in HEK-293T cells under hypoxia ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}A). To determine whether **MA04**, **MA07**, or **MA11** regulates HIF-1β, a transcription partner of HIF-1α, we performed Western blot analysis with antibody against HIF-1β. Compounds **MA04**, **MA07**, and **MA11** did not regulate HIF-1β as in the case of **1**, suggesting that **MA04**, **MA07**, and **MA11** regulate HIF-1α but not HIF-1β.

![Manassantin A (**1**), **MA04**, **MA07**, and **MA11** inhibit the expression of hypoxia-induced HIF-1α and HIF-1 target genes. (A) HEK-293T cells were treated with 1 μM of **1**, **MA04**, **MA07**, or **MA11** under hypoxia for 24 h. HIF-1α, HIF-1β, and Cdk6 expression levels were determined by Western blot analysis with β-actin as an internal control (N, normoxia; H, hypoxia). (B) Relative expression of VEGF mRNA was determined by real-time PCR after treatment of cells with 1 μM of **1**, **MA04**, **MA07**, or **MA11** under hypoxic conditions for 24 h. Relative expression of VEGF was normalized against β-actin (N, normoxia; H, hypoxia).](jm-2015-01220f_0013){#fig3}

To further confirm the effects of **MA04**, **MA07**, and **MA11** on HIF-1 activity, we determined the effect on HIF target genes at the transcriptional level. Upon treatment of **MA04**, **MA07**, or **MA11** at 1 μM, the protein level of cyclin-dependent kinase 6 (Cdk6), which is a HIF-1 target gene that regulates cell cycle progression, was decreased under hypoxic conditions ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}A). VEGF (a key angiogenic factor and a main target for HIF-1) mRNA levels were significantly reduced by **MA04** and to a lesser extent by **MA07** or **MA11** ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}B). All together, these data demonstrate that **MA04**, **MA07**, and **MA11** are inhibitors of HIF-1 activity. These compounds may serve as potential lead compounds for future *in vivo* animal and preclinical studies for novel anticancer drug development.

Photo-Cross-Linking Probes {#sec2.3}
--------------------------

Among various methods for molecular target identification,^[@ref40]^ small molecule affinity chromatography exploits the ability of small molecule probes to specifically bind to their molecular targets.^[@ref41]^ This approach has led to the discovery of important drug targets such as histone deacetylases^[@ref42]^ and splicing factor SF3b.^[@ref43]^ In particular, the approach can be very effective when a probe possesses an electrophile or a photo-cross-linking group to form a covalent linkage to its target proteins. Due to our strong interest in establishing the modes of action of manassantins, we designed and synthesized photo-cross-linking probes for future molecular target identification studies.

Among the commonly used photophores, the (3-trifluoromethyl)phenyldiazirine group is most popular owing to its wavelength for activation, the size of the photophore, cross-linking yields, side reactions, and stability of labeled products.^[@ref44]^ The carbene species generated from the diazirine group are strongly electrophilic and immediately insert into the target protein. On the basis of the SAR analysis described above, we designed two complementary photo-cross-linking probes (**MA13** and **MA14**) by incorporation of a (3-trifluoromethyl)phenyldiazirine group as the cross-linking group and an alkyne or a biotin as the handle for protein isolation ([Scheme [6](#sch6){ref-type="scheme"}](#sch6){ref-type="scheme"}). These photo-cross-linking probes (**MA13** and **MA14**) were easily prepared as illustrated in [Scheme [6](#sch6){ref-type="scheme"}](#sch6){ref-type="scheme"}. After the preparation of **MA13** and **MA14**, we evaluated the activity of **MA13** and **MA14** in the dual luciferase-reporter assay as described above. **MA13** and **MA14** showed IC~50~ values of 0.73 μM and 2.32 μM (see the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5b01220/suppl_file/jm5b01220_si_001.pdf) for details), respectively, which was in accordance with our SAR analysis. After further biological evaluations of **MA13**, we plan to use **MA13** in a small molecule affinity pull-down experiment side-by-side with other target identification approaches such as global gene expression^[@ref45],[@ref46]^ and energetics-based proteomics.^[@ref47],[@ref48]^

![Synthesis of Photo-cross-linking Probes (**MA13** and **MA14**)](jm-2015-01220f_0008){#sch6}

Conclusion {#sec3}
==========

Under hypoxia, tumors increase angiogenesis and metastatic potential, alter apoptosis, and regulate metabolism to cope with the stress of hypoxia. These adaptations make tumors more aggressive and treatment-resistant resulting in poor patient prognosis. HIF-1 is a main regulator of these adaptions through the activation of several hundred genes involved in angiogenesis, glucose transport, glycolytic pathway, ROS signals, erythropoiesis, and other processes. Due to the importance of HIF-1 in tumor development and progression, we have been exploring manassantins A (**1**) and B (**2**), potent inhibitors of HIF-1 activity isolated from *Saururus cernuus*, as effective therapeutics for cancers.

We prepared and evaluated a series of manassantin analogues for HIF-1α inhibition. The SAR study of manassantin analogues provided valuable insights into the role/function of the side chains of manassantins and their effects on hypoxia signaling. Among the analogues tested, **MA04**, **MA07**, and **MA11** with reduced structural complexity down-regulated hypoxia-induced HIF-1α protein stabilization and reduced the levels of Cdk6 and VEGF under hypoxia. Moreover, two photo-cross-linking probes (**MA13** and **MA14**) for molecular target identification were designed and synthesized on the basis of our SAR analysis. We expect that our findings will be an important basis for the future design of new manassantin analogues and optimization of drug-like properties of analogues for novel therapeutic development for cancers.

Experimental Section {#sec4}
====================

General Procedures {#sec4.1}
------------------

All reactions were conducted in oven-dried glassware under nitrogen. Unless otherwise stated all reagents were purchased from Sigma--Aldrich, Acros, or Fisher and were used without further purification. All solvents were ACS grade or better and used without further purification except tetrahydrofuran (THF), which was freshly distilled from sodium/benzophenone each time before use. Analytical thin layer chromatography (TLC) was performed with glass backed silica gel (60 Å) plates with fluorescent indication (Whatman). Visualization was accomplished by UV irradiation at 254 nm or by staining with *p*-anisaldehyde solution. Flash column chromatography was performed by using silica gel (particle size 230--400 mesh, 60 Å). All ^1^H NMR and ^13^C NMR spectra were recorded with a Varian 400 (400 MHz) and a Bruker 500 (500 MHz) spectrometer in CDCl~3~ by using the signal of residual CHCl~3~ as an internal standard. All NMR δ values are given in ppm, and all *J* values are in Hz. Electrospray ionization (ESI) mass spectrometry (MS) was recorded with an Agilent 1100 series (LC/MSD trap) spectrometer and performed to obtain the molecular masses of the compounds. Infrared (IR) absorption spectra were determined with a Thermo-Fisher (Nicolet 6700) spectrometer. Optical rotation values were measured with a Rudolph Research Analytical (A21102 API/1W) polarimeter. The percentage purity of compounds was above 95% as determined by HPLC.

### (*E*)-2-(Benzyloxy)-1-methoxy-4-(prop-1-en-1-yl)benzene (**7**) {#sec4.1.1}

To a cooled (0 °C) solution of the known *trans*-*m*-propenyl guaiacol (**6**;^[@ref31]^ 867 mg, 5.28 mmol) in dry DMF (13 mL, 0.4 M) were added NaH (60% dispersion in mineral oil, 304 mg, 7.92 mmol) and BnBr (0.63 mL, 5.28 mmol). The reaction mixture was allowed to warm to 25 °C. After stirring for 15 min, the reaction was quenched by addition of H~2~O and extracted with EtOAc. The combined organic layers were washed with brine, dried over anhydrous Na~2~SO~4~, and concentrated *in vacuo*. The residue was purified by column chromatography (silica gel, hexanes/EtOAc, 20/1) to afford **7** as a white powder (1.22 g, 91%): ^1^H NMR (400 MHz, CDCl~3~) δ 7.50 (d, *J* = 8.0 Hz, 2H), 7.41 (t, *J* = 8.0 Hz, 2H), 7.35 (d, *J* = 7.2 Hz, 1H), 6.98 (s, 1H), 6.92 (d, *J* = 7.2 Hz, 1H), 6.85 (d, *J* = 8.4 Hz, 1H), 6.34 (d, *J* = 15.6 Hz, 1H), 6.07 (dq, *J* = 6.8, 15.6 Hz, 1H), 5.19 (s, 2H), 3.89 (s, 3H), 1.89 (d, *J* = 6.8 Hz, 3H); ^13^C NMR (125 MHz, CDCl~3~) δ 148.9, 148.2, 137.2, 131.1, 130.6, 128.5, 127.4, 127.3, 123.6, 119.2, 111.8, 111.5, 71.0, 55.9, 18.3; IR (neat) 2932, 1510, 1258, 1136, 1024, 962 cm^--1^; HRMS (ESI) *m*/*z* 255.1389 \[(M + H)^+^, C~17~H~18~O~2~ requires 255.1380\].

### (1*S*,2*S*)-1-(3-(Benzyloxy)-4-methoxyphenyl)propane-1,2-diol (**8**) {#sec4.1.2}

To a cooled (0 °C) solution of AD-mix-α (5.06 g, 1.4 g/mmol of substrate) and MeSO~2~NH~2~ (344 mg, 3.62 mmol) in *t*-BuOH/H~2~O (1/2, 31.5 mL) was added dropwise alkene **7** (920 mg, 3.62 mmol) in EtOAc/*t*-BuOH (1/2, 16 mL). The reaction mixture was stirred for 2 days at 4 °C. The reaction was quenched by addition of sodium sulfite (5.42 g, 1.5 g/mmol of substrate), diluted with EtOAc, and stirred for 30 min at 25 °C. The layers were separated, and the aqueous layer was extracted with EtOAc. The combined organic layers were washed with 2 N KOH and brine, dried over anhydrous Na~2~SO~4~, and concentrated *in vacuo*. The residue was purified by column chromatography (silica gel, hexanes/EtOAc, 1/1) to afford **8** as a colorless oil (834 mg, 80%): ^1^H NMR (400 MHz, CDCl~3~) δ 7.42 (d, *J* = 7.2 Hz, 2H), 7.35 (t, *J* = 7.2 Hz, 2H), 7.29 (d, *J* = 7.2 Hz), 6.87--6.85 (m, 3H) 4.21 (d, *J* = 7.6 Hz, 1H), 3.86 (s, 1H), 3.72 (dq, *J* = 6.4, 14.0 Hz, 1H), 2.71 (br s, 2H), 0.94 (d, *J* = 6.4 Hz, 3H); ^13^C NMR (125 MHz, CDCl~3~) δ 149.4, 147.9, 136.9, 133.7, 128.4, 127.8, 127.5, 119.9, 113.0, 111.6, 79.1, 72.1, 71.0, 55.9, 18.7; IR (neat) 3383, 2970, 1733, 1513, 1256, 1134, 1021 cm^--1^; HRMS (ESI) *m*/*z* 311.1244 \[(M + Na)^+^, C~17~H~20~O~4~ requires 311.1254\].

### (*S*)-1-(3-(Benzyloxy)-4-methoxyphenyl)-2-hydroxypropan-1-one (**9**) {#sec4.1.3}

To a solution of diol **8** (834 mg, 2.89 mmol) in dioxane (29 mL, 0.1 M) was added DDQ (1.31 g, 5.78 mmol) at 25 °C. The reaction mixture was heated to 60 °C and stirred for 2 h at the same temperature. The reaction mixture was cooled to 0 °C, quenched by addition of saturated aqueous sodium thiosulfate and saturated aqueous NaHCO~3~, diluted with CH~2~Cl~2~, and stirred vigorously for 1 h. The layers were separated, and the aqueous layer was extracted with CH~2~Cl~2~. The combined organic layers were washed with brine, dried over anhydrous Na~2~SO~4~, and concentrated *in vacuo*. The residue was purified by column chromatography (silica gel, hexanes/EtOAc, 2/1) to afford **9** as a yellow oil (762 mg, 92%): ^1^H NMR (400 MHz, CDCl~3~) δ 7.56--7.52 (m, 2H), 7.47--7.45 (m, 2H), 7.39 (dd, *J* = 7.2, 8.0 Hz, 2H), 7.33 (d, *J* = 7.6 Hz, 1H), 6.93 (d, *J* = 8.4 Hz, 1H), 5.20 (s, 2H), 5.04 (q, *J* = 7.2 Hz, 1H), 3.96 (s, 3H), 1.37 (d, *J* = 7.2 Hz); ^13^C NMR (125 MHz, CDCl~3~) δ 200.7, 154.2, 148.3, 136.5, 128.7, 128.2, 127.5, 126.1, 123.8, 113.5, 110.8, 71.1, 68.9; IR (neat) 3459, 2976, 1667, 1594, 1512, 1263, 1114, 1016, 861 cm^--1^; HRMS (ESI) *m*/*z* 287.1269 \[(M + H)^+^, C~17~H~18~O~4~ requires 287.1278\].

### (*S*)-1-(3-(Benzyloxy)-4-methoxyphenyl)-1-oxopropan-2-yl-4-methylbenzenesulfonate (**10**) {#sec4.1.4}

To a cooled (0 °C) solution of hydroxyketone **9** (750 mg, 2.62 mmol) in pyridine (25 mL, 0.1 M) was added Ts~2~O (1.28 g, 3.93 mmol). After stirring for 40 min at the same temperature, the reaction was quenched by addition of saturated aqueous NH~4~Cl and extracted with CH~2~Cl~2~. The combined organic layers were washed with brine, dried over anhydrous Na~2~SO~4~, and concentrated *in vacuo*. The residue was purified by column chromatography (silica gel, hexanes/EtOAc, 2/1) to afford **10** as a white powder (935 mg, 81%): ^1^H NMR (400 MHz, CDCl~3~) δ 7.71 (d, *J* = 8.4 Hz, 2H), 7.54 (dd, *J* = 2.0, 8.8 Hz, 1H), 7.46--7.41 (m, 3H), 7.36--7.32 (m, 2H), 7.30--7.28 (m, 1H), 7.22 (d, *J* = 8.4 Hz, 2H), 6.86 (d, *J* = 8.8 Hz, 1H), 5.69 (q, *J* = 7.2 Hz, 1H), 5.12 (s, 2H), 3.90 (s, 3H), 2.36 (s, 3H), 1.48 (d, *J* = 7.2 Hz, 3H); ^13^C NMR (125 MHz, CDCl~3~) δ 192.9, 154.7, 148.3, 145.0, 136.5, 133.6, 129.8, 128.6, 128.1, 127.9, 127.6, 126.5, 123.9, 113.4, 110.7, 77.2, 71.0, 56.2, 21.6, 18.9; IR (neat) 2961, 1684, 1594, 1515, 1265, 1175, 1013, 932 cm^--1^; HRMS (ESI) *m*/*z* 441.1356 \[(M + H)^+^, C~24~H~24~O~6~S requires 441.1366\].

### (2*R*,2′*R*)-2,2′-({\[(2*S*,3*R*,4*R*,5*S*)-3,4-Dimethyltetrahydrofuran-2,5-diyl\]bis(2-methoxy-4,1-phenylene)}bis(oxy))bis(1-\[3-(benzyloxy)-4-methoxyphenyl\]propan-1-one) (**13**) {#sec4.1.5}

To a cooled (0 °C) solution of the known bis-phenol tetrahydrofuran core **5**([@ref24]) (54 mg, 0.16 mmol) in dry CH~2~Cl~2~ (2 mL, 0.08 M) was added dropwise 2-*tert*-butylimino-2-diethylamino-1,3-dimethylperhydro-1,3,2-diazaphosphorine (BEMP, 0.09 mL, 0.31 mmol). The resulting mixture was stirred at the same temperature for 10 min before tosylate **10** (207.2 mg, 0.47 mmol) in CH~2~Cl~2~ (2 mL, 0.23 M) was added. After stirring for 30 min at 0 °C, the reaction was quenched by addition of saturated aqueous NH~4~Cl and extracted with CH~2~Cl~2~. The combined organic layers were washed with brine, dried over anhydrous Na~2~SO~4~, and concentrated *in vacuo*. The residue was purified by column chromatography (silica gel, hexanes/EtOAc, 2/1) to afford **13** as a white foam (133 mg, 96%): ^1^H NMR (400 MHz, CDCl~3~) δ 7.82--7.76 (m, 4H), 7.46 (d, *J* = 7.6 Hz, 4H), 7.36 (dd, *J* = 7.2, 8.0 Hz, 4H), 7.31 (dd, *J* = 2.4, 7.2 Hz, 2H), 6.89 (d, *J* = 8.4 Hz, 2H), 6.82 (dd, *J* = 2.0, 10.0 Hz, 2H), 6.76--6.73 (m, 2H), 6.69 (dd, *J* = 1.6, 8.4 Hz, 2H), 5.36--5.32 (m, 4H), 5.17 (s, 4H), 3.92 (s, 6H), 3.83 (s, 6H), 2.23--2.17 (m, 2H), 1.64 (d, *J* = 6.8 Hz, 6H), 0.62 (d, *J* = 6.4 Hz, 6H); ^13^C NMR (125 MHz, CDCl~3~) δ 197.5, 154.2, 150.0, 147.9, 145.8, 136.6, 135.6, 128.6, 128.0, 127.6, 127.3, 123.9, 118.5, 115.7, 113.9, 110.6, 110.5, 83.4, 78.3, 70.8, 56.0, 44.0, 19.1, 14.8; IR (neat) 2961, 1684, 1593, 1509, 1265, 1137, 1020, 867 cm^--1^; HRMS (ESI) *m*/*z* 898.4169 \[(M + NH~4~)^+^, C~54~H~56~O~11~ requires 898.4161\].

### **MA01** {#sec4.1.5.1}

To a stirred solution of bis-benzyl ether **13** (29 mg, 0.03 mmol) in EtOAc (2 mL, 0.02M) was added 10% Pd--C (6 mg, 20 wt %). The resulting mixture was stirred under H~2~ atmosphere at 25 °C for 8 h. The reaction mixture was then filtered through Celite with EtOAc and concentrated *in vacuo*. The residue was purified by column chromatography (silica gel, hexanes/EtOAc, 3/2) to afford **MA01** as a white foam (22.1 mg, 96%): \[α\]^25.2^~D~ = −19.9 (*c* 0.73, CHCl~3~); ^1^H NMR (400 MHz, CDCl~3~) δ 7.73--7.68 (m, 4H), 6.87 (dd, *J* = 1.6, 8.4 Hz, 2H), 6.80 (dd, *J* = 1.6, 6.0 Hz, 2H), 6.77--6.73 (m, 2H), 6.67 (dd, *J* = 1.6, 8.4 Hz, 2H), 5.71 (br s, 2H), 5.40 (ddd, *J* = 6.8, 6.8, 6.8 Hz, 2H), 5.34 (d, *J* = 6.0 Hz), 3.93 (s, 6H), 3.83 (s, 6H), 2.20--2.16 (m, 2H), 1.67 (dd, *J* = 2.4, 6.8 Hz, 6H), 0.61 (d, *J* = 6.4 Hz, 6H); ^13^C NMR (125 MHz, CDCl~3~) δ 197.8, 151.1, 150.0, 146.0, 145.6, 135.8, 128.3, 122.7, 118.6, 116.4, 116.1, 115.2, 110.8, 110.1, 83.6, 78.2, 56.2, 44.1, 19.2, 14.8; IR (neat) 3404, 2962, 1684, 1608, 1509, 1272, 1139, 1028, 866 cm^--1^; HRMS (ESI) *m*/*z* 701.2951 \[(M + H)^+^, C~40~H~44~O~11~ requires 701.2956\].

### **MA02** {#sec4.1.5.2}

To a cooled (0 °C) solution of bis-phenol **MA01** (44 mg, 0.06 mmol) in dry CH~2~Cl~2~ (1.5 mL, 0.04 M) was added dropwise BEMP (0.04 mL, 0.13 mmol). The resulting mixture was stirred at the same temperature for 10 min before the known bromide **12**([@ref33]) (65 mg, 0.25 mmol) in CH~2~Cl~2~ (1.5 mL, 0.17 M) was added. After stirring for 1 h at 0 °C, the reaction was quenched by addition of saturated aqueous NH~4~Cl and extracted with CH~2~Cl~2~. The combined organic layers were washed with brine, dried over anhydrous Na~2~SO~4~, and concentrated *in vacuo*. The residue was purified by column chromatography (silica gel, hexanes/EtOAc, 1/2) to afford **MA02** as a yellow foam (52.6 mg, 80%): \[α\]^22.6^~D~ = 7.9 (*c* 0.66, CHCl~3~); ^1^H NMR (400 MHz, CDCl~3~) δ 7.86--7.82 (m, 2H), 7.61 (dd, *J* = 2.0, 6.4 Hz, 4H), 7.54 (s, 2H), 6.90 (dd, *J* = 6.0, 8.8 Hz, 4H), 6.79 (dd, *J* = 1.6, 8.8 Hz, 2H), 6.73 (dd, *J* = 4.8, 8.4 Hz, 2H), 6.68--6.64 (m, 2H), 5.40--5.31 (m, 8H), 3.95--3.92 (m, 18H), 3.80 (s, 6H), 2.19--2.15 (m, 2H), 1.65 (d, *J* = 6.8 Hz, 6H), 0.60 (d, *J* = 6.4 Hz, 6H); ^13^C NMR (125 MHz, CDCl~3~) δ 197.4, 192.2, 154.2, 154.0, 149.8, 149.4, 147.5, 145.8, 135.7, 127.8, 127.4, 124.7, 122.7, 118.5, 116.0, 113.8, 110.9, 110.7, 110.4, 110.3, 83.4, 78.3, 71.1, 56.2, 44.0, 19.1, 14.8; IR (neat) 2932, 1685, 1595, 1513, 1266, 1134, 1021, 870 cm^--1^; HRMS (ESI) *m*/*z* 1074.4497 \[(M + NH~4~)^+^, C~60~H~64~O~17~ requires 1074.4482\].

### **MA03** {#sec4.1.5.3}

To a solution of the known phenol **15**([@ref24]) (32 mg, 0.06 mmol) in acetone (3 mL, 0.02 M) was added K~2~CO~3~ (16.6 mg, 0.12 mmol) at 25 °C. After stirring for 1 h at 40 °C, the reaction mixture was cooled to 25 °C and treated with MeI (0.02 mL, 0.24 mmol) at the same temperature. After stirring for 2 h at reflux, the reaction mixture was cooled to 25 °C, diluted with EtOAc, and rinsed with saturated aqueous NH~4~Cl. The layers were separated, and the aqueous layer was extracted with EtOAc. The combined organic layers were washed with brine, dried over anhydrous Na~2~SO~4~, and concentrated *in vacuo*. The residue was purified by column chromatography (silica gel, hexanes/EtOAc, 1/1) to afford **MA03** as a white foam (31 mg, 93%): \[α\]^22.4^~D~ = −22.5 (*c* 0.13, EtOAc); ^1^H NMR (400 MHz, CDCl~3~) δ 7.84--7.80 (m, 1H), 7.68--7.66 (m, 1H), 6.87--6.67 (m, 7H), 5.44--5.36 (m, 3H), 3.93 (s, 3H), 3.91 (s, 3H), 3.87 (s, 3H), 3.86 (s, 3H), 3.85 (s, 3H), 2.25--2.19 (m, 2H), 1.71 (d, *J* = 6.8 Hz, 3H), 0.65 (dd, *J* = 6.4, 7.2 Hz, 3H); ^13^C NMR (125 MHz, CDCl~3~) δ 197.9, 153.7, 149.8, 149.1, 148.7, 148.0, 146.4, 145.9, 135.8, 134.0, 127.6, 123.7, 118.6, 115.9, 111.4, 110.9, 110.7, 110.2, 109.7, 109.0, 83.6, 78.5, 56.1, 44.2, 19.3, 14.9; IR (neat) 2960, 1682, 1593, 1512, 1261, 1136, 1023, 799 cm^--1^; HRMS (ESI) *m*/*z* 551.2631 \[(M + H)^+^, C~32~H~38~O~8~ requires 551.2639\].

### **MA04** {#sec4.1.5.4}

To a stirred solution of **MA03** (31 mg, 0.06 mmol) in MeOH (2 mL, 0.02 M) was added polymer-suppported borohydride (2 mmol BH~4~/g resin, 560 mg, 1.12 mmol). The reaction mixture was stirred with gentle agitation at 25 °C for 72 h. The polymer beads were then removed by filtration, and the filtrate was purified by column chromatography (silica gel, hexanes/EtOAc, 4/1) to afford **MA04** as a colorless oil (25 mg, 80%): \[α\]^22.5^~D~ = −78.3 (*c* 0.52, CHCl~3~); ^1^H NMR (400 MHz, CDCl~3~) δ 7.00--6.82 (m, 9H), 5.45 (d, *J* = 6.0 Hz, 2H), 4.64 (d, *J* = 8.4 Hz, 1H), 4.15--4.08 (m, 1H), 3.92 (s, 3H), 3.89 (s, 3H), 3.88 (s, 6H), 3.87 (s, 3H), 2.22--2.31 (m, 2H), 1.17 (d, *J* = 6.4 Hz, 3H), 0.71 (d, *J* = 6.4 Hz, 3H), 0.69 (dd, *J* = 6.4, 6.4 Hz, 3H); ^13^C NMR (125 MHz, CDCl~3~) δ 150.7, 149.1, 149.0, 148.8, 148.0, 146.6, 136.8, 134.0, 132.7, 120.1, 118.8, 118.5, 111.0, 110.9, 110.3, 110.2, 109.7, 84.3, 83.6, 83.5, 78.5, 56.0, 44.2, 17.2, 14.9; IR (neat) 3453, 2930, 1510, 1256, 1138, 1027, 811, 733 cm^--1^; HRMS (ESI) *m*/*z* 570.3072 \[(M + NH~4~)^+^, C~32~H~40~O~8~ requires 570.3061\].

### **MA06** {#sec4.1.5.5}

To a cooled (0 °C) solution of manassantin A (25 mg, 0.03 mmol) in THF (2 mL, 0.02 M) were added NaH (60% dispersion in mineral oil, 10.5 mg, 0.27 mmol) and MeI (0.02 mL, 0.34 mmol). After stirring for 1 h at the same temperature, the reaction was quenched by addition of H~2~O and extracted with EtOAc. The combined organic layers were washed with brine, dried over anhydrous Na~2~SO~4~, and concentrated *in vacuo*. The residue was purified by column chromatography (silica gel, hexanes/EtOAc, 2/1) to afford **MA06** as a colorless oil (23 mg, 79%): \[α\]^23.2^~D~ = −49.9 (*c* 0.3, CHCl~3~); ^1^H NMR (400 MHz, CDCl~3~) δ 6.97--6.77 (m, 12H), 5.42 (d, *J* = 6.4 Hz, 2H), 4.53--4.46 (m, 2H), 4.32 (d, *J* = 6.4 Hz, 2H), 3.90 (s, 6H), 3.89 (s, 6H), 3.85 (s, 6H), 3.29 (s, 6H), 2.28--2.22 (m, 2H), 1.06 (d, *J* = 6.4 Hz, 6H), 0.68 (d, *J* = 6.4 Hz, 6H); ^13^C NMR (125 MHz, CDCl~3~) δ 150.5, 149.2, 148.9, 146.8, 135.1, 131.4, 120.5, 118.7, 116.6, 110.8, 110.6, 86.6, 83.7, 79.0, 57.3, 56.2, 56.1, 44.2, 16.5, 15.0; IR (neat) 2933, 1508, 1271, 1028 cm^--1^; HRMS (ESI) *m*/*z* 778.4153 \[(M + NH~4~)^+^, C~44~H~56~O~11~ requires 778.4161\].

### **MA07** {#sec4.1.5.6}

To a cooled (0 °C) solution of the known bis-phenol **5** (90 mg, 0.26 mmol) in dry DMF (2 mL, 0.13 M) was added NaH (60% dispersion in mineral oil, 30 mg, 0.78 mmol). After stirring for 5 min, the reaction mixture was treated with the known bromide **12**([@ref33]) (271 mg, 1.04 mmol) in DMF (4 mL, 0.26 M) and stirred for 40 min. The resulting mixture was allowed to warm to 25 °C for 2 h. At 0 °C, the reaction was quenched by addition of saturated aqueous NH~4~Cl and extracted with EtOAc. The combined organic layers were washed with brine, dried over anhydrous Na~2~SO~4~, and concentrated *in vacuo*. The residue was purified by column chromatography (silica gel, hexanes/EtOAc, 1/1) to afford **MA07** as a colorless oil (90 mg, 47%): \[α\]^25.0^~D~ = −25.7 (*c* 0.4, EtOAc); ^1^H NMR (400 MHz, CDCl~3~) δ 7.67 (dd, *J* = 2.0, 8.4 Hz, 2H), 7.59 (s, 2H), 6.90--6.73 (m, 8H), 5.40 (d, *J* = 6.0 Hz, 2H), 5.28 (s, 4H), 3.95 (s, 6H), 3.93 (s, 6H), 3.89 (s, 6H), 2.26--2.20 (m, 2H), 0.66 (d, *J* = 6.4 Hz, 6H); ^13^C NMR (125 MHz, CDCl~3~) δ 193.5, 153.9, 149.5, 149.3, 146.6, 135.7, 128.0, 122.9, 118.5, 114.5, 110.6, 110.4, 110.2, 83.5, 72.4, 56.2, 56.1, 44.2, 14.9; IR (neat) 2931, 1689, 1512, 1261, 1163, 1021 cm^--1^; HRMS (ESI) *m*/*z* 701.2959 \[(M + H)^+^, C~40~H~44~O~11~ requires 701.2956\].

### **MA08** {#sec4.1.5.7}

To a cooled (−20 °C) solution of (*R*)-(+)-2-methyl-CBS-oxazaborolidine (0.69 mg, 2.5 μmol) and BH~3~·SMe~2~ (5 μL, 0.05 mmol) in toluene (1 mL, 0.05 M) was added dropwise ketone **MA07** (35 mg, 0.05 mmol) in toluene (2 mL, 0.03 M). After stirring for 1 h at the same temperature, the reaction was quenched by addition of MeOH followed by 1 N HCl. The aqueous layer was extracted with EtOAc, dried over anhydrous Na~2~SO~4~, and concentrated *in vacuo*. The residue was purified by column chromatography (silica gel, hexanes/EtOAc, 1/2) to afford **MA08** as a colorless oil (29 mg, 82%): \[α\]~D~ = −32.9 (*c* 0.4, EtOAc); ^1^H NMR (400 MHz, CDCl~3~) δ 7.01--6.80 (m, 12H), 5.44 (d, *J* = 6.0 Hz, 2H), 5.05 (dd, *J* = 2.8, 9.2 Hz, 2H), 4.15 (dd, *J* = 3.2, 10.4 Hz, 2H), 3.96 (t, *J* = 10.0 Hz, 2H), 3.894 (s, 6H), 3.89 (s, 6H), 3.87 (s, 6H), 3.30 (br s, 2H), 2.31--2.23 (m, 2H), 0.69 (d, *J* = 6.4 Hz, 6H); ^13^C NMR (125 MHz, EtOAc) δ 149.9, 149.2, 148.9, 146.9, 135.8, 132.3, 118.8, 118.7, 115.6, 111.1, 110.2, 109.5, 83.5, 76.5, 72.2, 56.0, 44.2, 14.9; IR (neat) 3481, 2922, 1514, 1262, 1027, 810 cm^--1^; HRMS (ESI) *m*/*z* 722.3523 \[(M + NH~4~)^+^, C~40~H~48~O~11~ requires 722.3535\].

### **MA09** {#sec4.1.5.8}

To a cooled (0 °C) solution of alcohol **MA08** (24 mg, 0.03 mmol) in dry DMF (3 mL, 0.01 M) were added NaH (60% dispersion in mineral oil, 20.5 mg, 0.55 mmol) and MeI (0.04 mL, 0.68 mmol). After stirring for 1 h at the same temperature, the reaction was quenched by addition of H~2~O and extracted with EtOAc. The combined organic layers were washed with brine, dried over anhydrous Na~2~SO~4~, and concentrated *in vacuo*. The residue was purified by column chromatography (silica gel, hexanes/EtOAc, 2/3) to afford **MA09** as a white foam (23 mg, 92%): \[α\]^22.0^~D~ = −43.2 (*c* 0.38, EtOAc); ^1^H NMR (400 MHz, CDCl~3~) δ 6.95--6.75 (m, 12H), 5.41 (d, *J* = 5.6 Hz, 2H), 4.60 (dd, *J* = 3.2, 7.6 Hz, 2H), 4.18 (dd, *J* = 8.0, 10.8 Hz, 2H), 4.02 (dd, *J* = 3.6, 6.8 Hz, 2H), 3.90 (s, 6H), 3.88 (s, 6H), 3.86 (s, 6H), 3.35 (s, 6H), 2.26--2.20 (m, 2H), 0.66 (d, *J* = 6.4 Hz, 6H); ^13^C NMR (125 MHz, CDCl~3~) δ 149.6, 149.3, 149.0, 135.0, 131.4, 119.6, 118.5, 114.1, 111.1, 110.5, 109.9, 83.6, 82.2, 74.0, 57.2, 56.1, 56.0, 44.2, 14.9; IR (neat) 2932, 1513, 1261, 1137, 1028 cm^--1^; HRMS (ESI) *m*/*z* 750.3846 \[(M + NH~4~)^+^, C~42~H~52~O~11~ requires 750.3848\].

### **MA10** {#sec4.1.5.9}

To a solution of the known bis-phenol **5** (20 mg, 0.06 mmol) in dry DMF (1.5 mL, 0.04 M) were added K~2~CO~3~ (32 mg, 0.23 mmol) and 3,4-dimethoxyphenethyl bromide (143 mg, 0.58 mmol) at 25 °C. The reaction mixture was heated to 120 °C and stirred for 30 h at the same temperature. The reaction was quenched by addition of saturated aqueous NH~4~Cl and extracted with EtOAc. The combined organic layers were washed with brine, dried over anhydrous Na~2~SO~4~, and concentrated *in vacuo*. The residue was purified by column chromatography (silica gel, hexanes/EtOAc, 3/1) to afford **MA10** as a yellow oil (18 mg, 44%): \[α\]^21.8^~D~ = −6.79 (*c* 0.28, EtOAc); ^1^H NMR (400 MHz, CDCl~3~) δ 6.87--6.82 (m, 12H), 5.43 (d, *J* = 6.0 Hz, 2H), 4.19 (t, *J* = 7.2 Hz, 4H), 3.88--3.87 (m, 18H), 3.10 (t, *J* = 7.2 Hz, 4H), 2.29--2.22 (m, 2H), 0.68 (d, *J* = 6.0 Hz, 6H); ^13^C NMR (125 MHz, CDCl~3~) δ 149.2, 149.0, 147.8, 147.3, 134.5, 130.9, 121.1, 118.6, 112.9, 112.6, 111.4, 110.3, 83.6, 70.2, 56.2, 56.1, 55.9, 56.2, 56.1, 55.9, 44.2, 35.6, 14.9; IR (neat) 2928, 1507, 1229, 1138, 1026 cm^--1^; HRMS (ESI) *m*/*z* 690.3632 \[(M + NH~4~)^+^, C~40~H~48~O~9~ requires 690.3637\].

### (1*S*,2*S*)-1-Phenylpropane-1,2-diol (**18**) {#sec4.1.6}

To a cooled (0 °C) solution of AD-mix-α (5.4 g, 1.4 g/mmol of substrate) and MeSO~2~NH~2~ (367 mg, 3.85 mmol) in *t*-BuOH/H~2~O (1/2, 30 mL) was added dropwise *trans*-β-methylstyrene **17** (0.5 mL, 3.85 mmol) in *t*-BuOH (10 mL). The reaction mixture was stirred for 48 h at 4 °C. The reaction was quenched by addition of sodium sulfite (5.78 g, 1.5 g/mmol of substrate), diluted with EtOAc, and stirred for 30 min at 25 °C. The layers were separated, and the aqueous layer was extracted with EtOAc. The combined organic layers were washed with 2 N KOH and brine, dried over anhydrous Na~2~SO~4~, and concentrated *in vacuo*. The residue was purified by column chromatography (silica gel, hexanes/EtOAc, 3/1) to afford **18** as a colorless oil (539 mg, 92%): ^1^H NMR (400 MHz, CDCl~3~) δ 7.33--7.23 (m, 5H), 4.25 (d, *J* = 7.6 Hz, 1H), 4.02 (br s, 2H), 3.77 (dq, *J* = 6.4, 13.6 Hz, 1H), 0.95 (d, *J* = 6.4 Hz, 3H); ^13^C NMR (125 MHz, CDCl~3~) δ 141.2, 128.4, 128.0, 127.0, 79.5, 72.1; IR (neat) 3362, 2973, 1454, 1265, 1128, 1036, 870 cm^--1^; HRMS (ESI) *m*/*z* 135.0804 \[M + H--H~2~O, C~9~H~12~O~2~ requires 135.0804\].

### (*S*)-2-Hydroxy-1-phenylpropan-1-one (**19**) {#sec4.1.7}

To a solution of diol **18** (539 mg, 3.54 mmol) in dioxane (35 mL, 0.1 M) was added DDQ (1.6 g, 7.08 mmol) at 25 °C. The reaction mixture was heated to 80 °C and stirred for 12 h at the same temperature. The reaction mixture was cooled to 0 °C, quenched by addition of saturated aqueous sodium thiosulfate and saturated aqueous NaHCO~3~, diluted with CH~2~Cl~2~, and stirred vigorously for 1 h. The layers were separated, and the aqueous layer was extracted with CH~2~Cl~2~. The combined organic layers were washed with brine, dried over anhydrous Na~2~SO~4~, and concentrated *in vacuo*. The residue was purified by column chromatography (silica gel, hexanes/EtOAc, 2/1) to afford **19** as a colorless crystal (308 mg, 58%): ^1^H NMR (400 MHz, CDCl~3~) δ 7.92 (dd, *J* = 1.2, 8.4 Hz, 2H), 7.63--7.58 (m, 1H), 7.49 (dt, *J* = 1.6, 7.6, 14.0 Hz, 2H), 5.16 (q, *J* = 7.2 Hz, 1H), 3.73 (br s, 1H), 1.44 (d, *J* = 7.2 Hz, 3H); ^13^C NMR (125 MHz, CDCl~3~) δ 202.6, 134.1, 133.5, 128.9, 69.5, 22.4; IR (neat) 3455, 2979, 1679, 1597, 1268, 1126, 1025, 968 cm^--1^; HRMS (ESI) *m*/*z* 133.0647 \[(M + H -- H~2~O)^+^, C~9~H~10~O~2~ requires 133.0648\].

### (*S*)-1-Oxo-1-phenylpropan-2-yl 4-methylbenzenesulfonate (**20**) {#sec4.1.8}

To a cooled (0 °C) solution of hydroxyketone **19** (308 mg, 2.05 mmol) in pyridine (20 mL, 0.1 M) was added Ts~2~O (1 g, 3.08 mmol). After stirring for 30 min at the same temperature, the reaction was quenched by addition of saturated aqueous NH~4~Cl and extracted with CH~2~Cl~2~. The combined organic layers were washed with brine, dried over anhydrous Na~2~SO~4~, and concentrated *in vacuo*. The residue was purified by column chromatography (silica gel, hexanes/EtOAc, 2/1) to afford **20** as a white powder (437 mg, 70%): ^1^H NMR (400 MHz, CDCl~3~) δ 7.87 (dd, *J* = 1.2, 8.4 Hz, 2H), 7.75 (dd, *J* = 1.2, 8.4 Hz, 2H), 7.61--7.56 (m, 1H), 7.45 (dt, *J* = 1.6, 8.0, 13.6 Hz, 2H), 7.26 (d, *J* = 8.0 Hz, 2H), 5.78 (q, *J* = 7.2 Hz, 1H), 2.40 (s, 3H), 1.59 (d, *J* = 7.2 Hz, 3H); ^13^C NMR (125 MHz, CDCl~3~) δ 194.9, 145.2, 134.0, 133.8, 133.6, 129.9, 128.9, 128.0, 77.5, 21.7, 18.8; IR (neat) 2960, 1699, 1597, 1360, 1175, 1017, 919 cm^--1^; HRMS (ESI) *m*/*z* 305.0836 \[(M + H)^+^, C~16~H~16~O~4~S requires 305.0842\].

### **MA11** {#sec4.1.8.1}

To a cooled (0 °C) solution of the known bis-phenol **5** (30 mg, 0.09 mmol) in dry CH~2~Cl~2~ (1.5 mL, 0.06 M) was added dropwise BEMP (0.05 mL, 0.17 mmol). The resulting mixture was stirred at the same temperature for 10 min before tosylate **20** (106 mg, 0.35 mmol) in CH~2~Cl~2~ (1.5 mL, 0.23 M) was added. After stirring for 30 min at 0 °C, the reaction was quenched by addition of saturated aqueous NH~4~Cl and extracted with CH~2~Cl~2~. The combined organic layers were washed with brine, dried over anhydrous Na~2~SO~4~, and concentrated *in vacuo*. The residue was purified by column chromatography (silica gel, hexanes/EtOAc, 4/1) to afford **MA11** as a colorless oil (45.5 mg, 86%): \[α\]^23.4^~D~ = −27.57 (*c* 0.5, CHCl~3~); ^1^H NMR (400 MHz, CDCl~3~) δ 8.11--8.08 (m, 4H), 7.58--7.54 (m, 2H), 7.45 (dd, *J* = 6.0, 7.2 Hz, 4H), 6.82--6.77 (m, 4H), 6.70--6.66 (m, 2H), 5.46 (dq, *J* = 4.0, 6.8 Hz, 2H), 5.35 (d, *J* = 6.0 Hz, 2H), 3.82 (s, 6H), 2.22--2.16 (m, 2H), 1.70 (d, *J* = 7.2 Hz, 6H), 0.62 (d, *J* = 6.4 Hz, 6H); ^13^C NMR (125 MHz, CDCl~3~) δ 199.3, 150.0, 145.9, 136.0, 134.8, 133.5, 129.1, 128.7, 118.6, 116.7, 116.5, 110.7, 83.5, 78.5, 56.1, 44.2, 30.0, 19.0, 14.9; IR (neat) 2962, 1697, 1508, 1269, 1221, 1142, 1034, 966 cm^--1^; HRMS (ESI) *m*/*z* 626.3107 \[(M + NH~4~)^+^, C~38~H~40~O~7~ requires 626.3112\].

### **MA12** {#sec4.1.8.2}

To a stirred solution of **11** (42 mg, 0.07 mmol) in MeOH (4.5 mL, 0.02 M) was added polymer-suppported borohydride (2 mmol BH~4~/g resin, 690 mg, 1.38 mmol). The reaction mixture was stirred with gentle agitation at 25 °C for 48 h. The polymer beads were then removed by filtration, and the filtrate was purified by column chromatography (silica gel, hexanes/EtOAc, 2/1) to afford **MA12** as a colorless oil (23 mg, 54%): \[α\]^22.7^~D~ = −62.14 (*c* 0.4, EtOAc); ^1^H NMR (400 MHz, CDCl~3~) δ 7.41--7.28 (m, 10H), 7.00--6.81 (m, 6H), 5.46 (d, *J* = 6.0 Hz, 2H), 4.70 (d, *J* = 8.0 Hz, 2H), 4.18--4.09 (m, 3H), 3.93 (s, 6H), 2.32--2.26 (m, 2H), 1.17 (dd, *J* = 2.0, 6.4 Hz, 6H), 0.72 (d, *J* = 6.4 Hz, 6H); ^13^C NMR (125 MHz, CDCl~3~) δ 150.7, 146.6, 140.2, 136.7, 128.5, 128.2, 127.5, 119.0, 118.8, 110.3, 84.3, 83.5, 78.8, 56.0, 44.3, 17.1, 15.0; IR (neat) 3481, 2964, 1508, 1258, 1036 cm^--1^; HRMS (ESI) *m*/*z* 630.3447 \[(M + NH~4~)^+^, C~38~H~44~O~7~ requires 630.3425\].

### (*E*)-2,2,2-Trifluoro-1-\[4-(prop-1-en-1-yl)phenyl\]ethan-1-one (**22**) {#sec4.1.9}

To a cooled (−78 °C) solution of (*E*)-1-bromo-4-(prop-1-en-1-yl)benzene^[@ref49]^ (340 mg, 1.73 mmol) in dry THF (15 mL, 0.12 M) was added dropwise *n*-BuLi (2.3 M in hexane, 1.13 mL, 2.59 mmol). The resulting mixture was stirred for 2 h at the same temperature before methyl fluoroacetate (0.23 mL, 2.24 mmol) in dry THF (9 mL) was added dropwise. After stirring for 1.5 h at the same temperature, the reaction was quenched by addition of saturated aqueous NH~4~Cl, and the resulting mixture was extracted with Et~2~O. The combined organic layers were washed with brine, dried over anhydrous Na~2~SO~4~, and concentrated *in vacuo*. The residue was purified by column chromatography (silica gel, hexanes) to afford ketone **22** (337 mg, 90%): ^1^H NMR (400 MHz, CDCl~3~) δ 8.00 (d, *J* = 8.0 Hz, 2H), 7.46 (d, *J* = 8.4 Hz, 2H), 6.51--6.43 (m, 2H), 1.95 (d, *J* = 5.2 Hz, 3H).

### (Z)-2,2,2-Trifluoro-1-{4-\[(*E*)-prop-1-en-1-yl\]phenyl}ethan-1-one *O*-Tosyl Oxime (**23**) {#sec4.1.10}

#### Oxime Formation {#sec4.1.10.1}

To a solution of **22** (337 mg, 1.57 mmol) in pyridine/EtOH (2:1, 6 mL) was added hydroxylamine hydrochloride (142 mg, 2.05 mmol) at 25 °C. After stirring for 1.5 h at reflux, the solvents were removed under reduced pressure. The residue was extracted with EtOAc/H~2~O, dried over anhydrous Na~2~SO~4~, and concentrated *in vacuo*. The crude residue was employed in the next step without further purification.

#### Tosylation {#sec4.1.10.2}

To a solution of the crude oxime (348 mg, 1.52 mmol) in pyridine (6 mL, 0.25 M) was added TsCl (434 mg, 2.28 mmol) at 25 °C. After stirring for 2 h at reflux, the solvents were removed under reduced pressure. The residue was extracted with EtOAc/H~2~O, dried over anhydrous Na~2~SO~4~, and concentrated *in vacuo*. The residue was purified by column chromatography (silica gel, hexanes/EtOAc, 20/1) to afford tosyloxime **23** as a yellow powder (555 mg, 92% for 2 steps): ^1^H NMR (400 MHz, CDCl~3~) δ 7.91 (dd, *J* = 8.4, 14.4 Hz, 2H), 7.42--7.36 (m, 6H), 6.38 (dd, *J* = 4.0, 9.6 Hz, 2H), 2.48 (d, *J* = 5.6 Hz, 3H), 1.92 (d, *J* = 5.2 Hz, 3H).

### (*E*)-3-\[4-(Prop-1-en-1-yl)phenyl\]-3-(trifluoromethyl)diaziridine (**24**) {#sec4.1.11}

To a cooled (−78 °C) solution of **23** (550 mg, 1.43 mmol) in CH~2~Cl~2~ (10 mL, 0.14 M) was bubbled NH~3~ gas. The resulting mixture was stirred in a sealed tube for 5 min at −78 °C and slowly warmed to 25 °C. After stirring for 12 h at the same temperature, the reaction mixture was cooled to −78 °C, and NH~3~ was evaporated for 6 h at 25 °C. The solid was removed by filtration. The filtrate was washed with water and extracted with CH~2~Cl~2~. The combined organic layers were washed with brine, dried over anhydrous Na~2~SO~4~, and concentrated *in vacuo*. The residue was purified by column chromatography (silica gel, hexanes/EtOAc, 10/1) to afford diaziridine **24** (296 mg, 90%): ^1^H NMR (400 MHz, CDCl~3~) δ 7.53--7.49 (m, 2H), 7.37--7.32 (m, 2H), 6.43--6.36 (m, 1H), 6.30 (dq, *J* = 6.4, 19.2 Hz, 1H), 2.77 (br s, 1H), 2.20 (br s, 1H), 1.91--1.86 (m, 3H).

### (1*S*,2*S*)-1-(4-\[3-(Trifluoromethyl)-3*H*-diazirin-3-yl\]phenyl)propane-1,2-diol (**25**) {#sec4.1.12}

#### Oxidation {#sec4.1.12.1}

To a solution of **24** (290 mg, 1.27 mmol) in dry Et~2~O (10 mL, 0.13 M) was added a freshly prepared Ag~2~O (883 mg, 3.81 mmol) at 25 °C. After stirring for 1 h at the same temperature, the reaction mixture was filtered through Celite. The organic layers were dried over anhydrous Na~2~SO~4~ and concentrated *in vacuo*. The crude residue was employed in the next step without further purification.

#### Dihydroxylation {#sec4.1.12.2}

To a cooled (0 °C) solution of AD-mix-α (1.5 g, 1.4 g/mmol of substrate) and MeSO~2~NH~2~ (103 mg, 1.08 mmol) in *t*-BuOH/H~2~O (1/2, 12 mL) was added dropwise the crude alkene (244 mg, 1.08 mmol) in *t*-BuOH (4 mL, 0.27 M). The reaction mixture was stirred for 40 h at 4 °C. The reaction was quenched by addition of sodium sulfite (1.55 g, 1.5 g/mmol of substrate). The resulting mixture was diluted with EtOAc and stirred for 30 min at 25 °C. The layers were separated, and the aqueous layer was extracted with EtOAc. The combined organic layers were washed with 2 N KOH and brine, dried over anhydrous Na~2~SO~4~, and concentrated *in vacuo*. The residue was purified by column chromatography (silica gel, hexanes/EtOAc, 3/2) to afford diol **25** (255 mg, 77% for 2 steps): ^1^H NMR (400 MHz, CDCl~3~) δ 7.38 (d, *J* = 8.4 Hz, 2H), 7.18 (d, *J* = 8.4 Hz, 2H), 4.40 (d, *J* = 7.2 Hz, 1H), 3.81 (m, 1H), 2.42 (br s, 2H), 1.07 (d, *J* = 6.4 Hz, 3H).

### (*S*)-1-Oxo-1-(4-\[3-(trifluoromethyl)-3*H*-diazirin-3-yl\]phenyl)propan-2-yl 4-methylbenzenesulfonate (**26**) {#sec4.1.13}

#### Oxidation {#sec4.1.13.1}

To a cooled (0 °C) solution of **25** (100 mg, 0.38 mmol) in CH~2~Cl~2~ (10 mL, 0.04 M) was added DMDO (0.1 M in acetone, 8.5 mL, 0.85 mmol). After stirring for 18 h at the same temperature, the solvents were removed under reduced pressure. The residue was purified by column chromatography (silica gel, hexanes/EtOAc, 4/1) to afford the corresponding hydroxy ketone **S1** (29 mg, 29%): ^1^H NMR (400 MHz, CDCl~3~) δ 7.95 (d, *J* = 8.8 Hz, 2H), 7.31 (d, *J* = 8.0 Hz, 2H), 5.14 (dq, *J* = 6.4, 6.8 Hz, 1H), 3.65 (d, *J* = 6.8, 1H), 1.44 (d, *J* = 6.8 Hz, 3H).

#### Tosylation {#sec4.1.13.2}

To a cooled (0 °C) solution of **S1** (29 mg, 0.11 mmol) in pyridine (3 mL, 0.04 M) was added Ts~2~O (55 mg, 0.17 mmol). After stirring for 30 min at the same temperature, the reaction was quenched by addition of saturated aqueous NH~4~Cl and the resulting mixture was extracted with CH~2~Cl~2~. The combined organic layers were washed with brine, dried over anhydrous Na~2~SO~4~, and concentrated *in vacuo*. The residue was purified by column chromatography (silica gel, hexanes/EtOAc, 5/1) to afford tosylate **26** as a white powder (36 mg, 76%): ^1^H NMR (400 MHz, CDCl~3~) δ 7.91 (d, *J* = 8.8 Hz, 2H), 7.72 (d, *J* = 8.4 Hz, 2H), 7.26 (dd, *J* = 8.4, 8.4 Hz, 4H), 5.67 (q, *J* = 6.8 Hz, 1H), 2.42 (s, 3H), 1.58 (d, *J* = 6.8 Hz, 3H).

### (*R*)-1-\[3-(Benzyloxy)-4-methoxyphenyl\]-2-(4-\[(2*S*,3*R*,4*R*,5*S*)-5-(4-hydroxy-3-methoxyphenyl)-3,4-dimethyltetrahydrofuran-2-yl\]-2-methoxyphenoxy)propan-1-one (**27**) {#sec4.1.14}

To a cooled (0 °C) solution of the known bis-phenol **5** (35 mg, 0.1 mmol) in dry CH~2~Cl~2~ (1 mL, 0.1 M) was added dropwise BEMP (0.03 mL, 0.1 mmol). The resulting mixture was stirred at the same temperature for 10 min before tosylate **10** (45 mg, 0.1 mmol) in CH~2~Cl~2~ (1 mL, 0.1 M) was added. After stirring for 30 min at 0 °C, the reaction was quenched by addition of saturated aqueous NH~4~Cl and extracted with CH~2~Cl~2~. The combined organic layers were washed with brine, dried over anhydrous Na~2~SO~4~, and concentrated *in vacuo*. The residue was purified by column chromatography (silica gel, hexanes/EtOAc, 1/1) to afford phenol **27** (25 mg, 40%): ^1^H NMR (400 MHz, CDCl~3~) δ 7.82--7.76 (m, 2H), 7.47 (d, *J* = 7.2 Hz, 2H), 7.37 (dd, *J* = 7.2, 7.6 Hz, 2H), 7.31 (d, *J* = 7.6 Hz, 1H), 6.89 (dd, *J* = 6.0, 8.4 Hz, 2H), 6.83 (dd, *J* = 2.0, 13.2 Hz, 2H), 6.77--6.68 (m, 3H), 5.54 (s, 1H), 5.39 (dd, *J* = 5.2, 6.0 Hz, 2H), 5.34 (dd, *J* = 4.4, 6.8 Hz, 1H), 5.18 (s, 2H), 3.93 (s, 3H), 3.89 (s, 3H), 3.84 (s, 3H), 2.24--2.20 (m, 2H), 1.64 (d, *J* = 6.8 Hz, 3H), 0.67--0.64 (m, 6H).

### (*R*)-2-(4-{2*S*,3*R*,4*R*,5*S*)-5-(4-\[(*tert*-Butyldiphenylsilyl)oxy\]-3-methoxyphenyl)-3,4-dimethyltetrahydrofuran-2-yl}-2-methoxyphenoxy)-1-(3-hydroxy-4-methoxyphenyl)propan-1-one (**28**) {#sec4.1.15}

#### TBDPS Protection {#sec4.1.15.1}

To a cooled (0 °C) solution of **27** (18 mg, 0.03 mmol) in dry CH~2~Cl~2~ (2 mL, 0.02 M) were added imidazole (12 mg, 0.18 mmol) and TBDPSCl (0.02 mL, 0.09 mmol). After stirring for 10 h at the same temperature, the reaction was quenched by addition of saturated aqueous NH~4~Cl, and the resulting mixture was extracted with CH~2~Cl~2~. The combined organic layers were washed with brine, dried over anhydrous Na~2~SO~4~, and concentrated *in vacuo*. The residue was purified by column chromatography (silica gel, hexanes/EtOAc, 3/1) to afford the corresponding ether **S2** as a white foam (24 mg, 95%): ^1^H NMR (400 MHz, CDCl~3~) δ 7.81--7.68 (m, 6H), 7.47--7.29 (m, 11H), 6.89 (d, J = 8.4 Hz, 1H), 6.82--6.66 (m, 5H), 6.53 (d, J = 8.4 Hz, 1H), 5.34--5.31 (m, 3H), 5.17 (s, 2H), 3.93 (s, 3H), 3.82 (s, 3H), 3.54 (s, 3H), 2.19--2.12 (m, 2H), 1.64 (d, *J* = 6.8 Hz, 3H), 1.11 (s, 9H), 0.59 (dd, *J* = 6.4, 16.0 Hz, 6H).

#### Bn Deprotection {#sec4.1.15.2}

To a stirred solution of **S2** (102 mg, 0.12 mmol) in EtOAc/EtOH (3/1, 12 mL, 0.1 M) was added 10% Pd/C (30 mg, 30 wt %). The resulting mixture was stirred under H~2~ atmosphere at 25 °C for 8 h. The reaction mixture was then filtered through Celite with EtOAc and concentrated *in vacuo*. The residue was purified by column chromatography (silica gel, hexanes/EtOAc, 2/1) to afford phenol **28** (62 mg, 67%): ^1^H NMR (400 MHz, CDCl~3~) δ 7.74--7.68 (m, 6H), 7.40--7.29 (m, 6H), 6.88 (dd, *J* = 2.0, 8.4 Hz, 1H), 6.81 (dd, *J* = 2.0, 6.0 Hz, 1H), 6.75 (dd, *J* = 4.4, 8.4 Hz, 1H), 6.70--6.66 (m, 3H), 6.55--6.52 (m, 1H), 5.61 (s, 1H), 5.39 (m, 1H), 5.32 (d, *J* = 4.8 Hz, 2H), 3.95 (s, 3H), 3.84 (s, 3H), 3.54 (s, 3H), 2.18--2.12 (m, 2H), 1.68 (dd, *J* = 2.0, 6.4 Hz, 3H), 1.11 (s, 9H), 0.59 (dd, *J* = 6.4, 13.2 Hz, 6H).

### **MA13** {#sec4.1.16}

To a cooled (0 °C) solution of **28** (20 mg, 0.03 mmol) in dry DMF (2 mL, 0.01 M) were added propargyl bromide (0.02 mL, 0.03 mmol) and K~2~CO~3~ (5.5 mg, 0.04 mmol). After stirring for 1 h at 25 °C, the reaction was quenched by addition of water, and the resulting mixture was extracted with EtOAc. The combined organic layers were washed with brine, dried over anhydrous Na~2~SO~4~, and concentrated *in vacuo*. The residue was purified by column chromatography (silica gel, hexanes/EtOAc, 2/1) to afford the corresponding ether **S3** as a white foam (14 mg, 67%): ^1^H NMR (400 MHz, CDCl~3~) δ 7.88--7.84 (m, 2H), 7.69 (dd, *J* = 1.6, 8.0 Hz, 4H), 7.40--7.30 (m, 6H), 6.90 (d, *J* = 8.0 Hz, 1H), 6.81 (dd, *J* = 1.6, 9.2 Hz, 1H), 6.77 (dd, *J* = 3.6, 8.0 Hz, 1H), 6.70--6.65 (m, 3H), 6.53 (dd, *J* = 1.6, 8.4 Hz, 1H), 5.37 (dq, *J* = 4.4, 6.8 Hz, 1H), 5.33--5.30 (m, 2H), 4.80 (d, *J* = 2.4 Hz, 2H), 3.93 (s, 3H), 3.84 (s, 3H), 3.54 (s, 3H), 2.51 (s, 1H), 2.19--2.12 (m, 2H), 1.71 (d, *J* = 6.8 Hz, 3H), 1.11 (s, 9H), 0.59 (dd, *J* = 6.4, 15.6 Hz, 6H).

#### TBDPS Deprotection {#sec4.1.16.1}

To a solution of **S3** (14 mg, 0.02 mmol) in dry THF (1 mL, 0.02 M) was added TBAF (1.0 M in THF, 0.04 mL, 0.04 mmol). After stirring for 5 min at 25 °C, the reaction was quenched by addition of saturated aqueous NH~4~Cl, and the resulting mixture was extracted with EtOAc. The combined organic layers were washed with brine, dried over anhydrous Na~2~SO~4~, and concentrated *in vacuo*. The residue was purified by column chromatography (silica gel, hexanes/EtOAc, 2/1) to afford the corresponding phenol **S4** (8 mg, 80%): ^1^H NMR (500 MHz, CDCl~3~) δ 7.79--7.84 (m, 2H), 6.92--6.68 (m, 7H), 5.52 (s, 1H), 5.40--5.36 (m, 3H), 4.81 (d, *J* = 2.0 Hz, 2H), 3.93 (s, 3H), 3.89 (s, 3H), 3.85 (s, 3H), 2.51 (s, 1H), 2.24--2.18 (m, 2H), 1.71 (d, *J* = 7.0 Hz, 3H), 0.67--0.64 (m, 6H).

#### Alkylation {#sec4.1.16.2}

To a cooled (0 °C) solution of **S4** (8 mg, 0.01 mmol) in dry CH~2~Cl~2~ (1 mL, 0.01 M) was added dropwise BEMP (0.004 mL, 0.01 mmol). The resulting mixture was stirred at the same temperature for 10 min before tosylate **26** (7 mg, 0.02 mmol) in CH~2~Cl~2~ (0.5 mL, 0.04 M) was added. After stirring for 30 min at 0 °C, the reaction was quenched by addition of saturated aqueous NH~4~Cl, and the resulting mixture was extracted with CH~2~Cl~2~. The combined organic layers were washed with brine, dried over anhydrous Na~2~SO~4~, and concentrated *in vacuo*. The residue was purified by column chromatography (silica gel, hexanes/EtOAc, 2/1) to afford **MA13** as a colorless oil (5 mg, 45%): ^1^H NMR (400 MHz, CDCl~3~) δ 8.15 (dd, *J* = 4.8, 8.4 Hz, 2H), 7.88--7.84 (m, 2H), 7.23 (d, *J* = 8.4 Hz, 2H), 6.90 (d, *J* = 8.4 Hz, 1H), 6.82--6.76 (m, 4H), 6.70--6.66 (m, 2H), 5.40--5.33 (m, 4H), 4.80 (d, *J* = 2.4 Hz, 2H), 3.93 (s, 3H), 3.84 (s, 3H), 3.80 (s, 3H), 2.51 (s, 1H), 2.21--2.18 (m, 2H), 1.69 (dd, *J* = 6.8, 16.0 Hz, 6H), 0.63--0.60 (m, 6H); IR (neat) 2960, 1684, 1509, 1264, 1025 cm^--1^; HRMS (ESI) *m*/*z* 823.2803 \[(M + Na)^+^, C~44~H~43~F~3~N~2~O~9~ requires 823.2813\].

### *tert*-Butyl \[2-(2-{2-\[2-Methoxy-5-((*R*)-2-\[2-methoxy-4-((2*S*,3*R*,4*R*,5*S*)-5-{3-methoxy-4-(\[(*R*)-1-oxo-1-{4-\[3-(trifluoromethyl)-3*H*-diazirin-3-yl\]phenyl}propan-2-yl\]oxy)phenyl}-3,4-dimethyltetrahydrofuran-2-yl)phenoxy\]propanoyl)phenoxy\]ethoxy}ethoxy)ethyl\]carbamate (**29**) {#sec4.1.17}

#### Linker Attachment {#sec4.1.17.1}

To a solution of **28** (15 mg, 0.02 mmol) in dry DMF (2 mL, 0.01 M) was added K~2~CO~3~ (6 mg, 0.04 mmol) at 25 °C. After stirring for 30 min at the same temperature, the reaction mixture was cooled to 0 °C and treated with *tert*-butyl (2-\[2-(2-bromoethoxy)ethoxy\]ethyl)carbamate^[@ref50]^ (7.5 mg, 0.02 mmol) and TBAI (0.8 mg, 0.002 mmol). After stirring for 16 h at 25 °C, the reaction was quenched by addition of water, and the resulting mixture was extracted with EtOAc. The combined organic layers were washed with brine, dried over anhydrous Na~2~SO~4~, and concentrated *in vacuo*. The residue was purified by column chromatography (silica gel, hexanes/EtOAc, 1/2) to afford the corresponding phenol **S5** (5 mg, 34%): ^1^H NMR (400 MHz, CDCl~3~) δ 7.82 (dd, *J* = 6.0, 8.4 Hz, 1H), 7.70 (s, 1H), 6.89--6.67 (m, 7H), 5.54 (s, 1H), 5.41--5.38 (m, 3H), 5.15 (br s, 1H), 4.23 (dd, *J* = 4.8, 4.8 Hz, 2H), 3.91--3.89 (m, 5H), 3.89 (s, 3H), 3.85 (s, 3H), 3.72 (dd, *J* = 4.0, 4.8 Hz, 2H), 3.63 (dd, *J* = 4.0, 5.2 Hz, 2H), 3.54 (dd, *J* = 4.8, 5.2 Hz, 2H), 3.31 (d, *J* = 4.8 Hz, 2H), 2.24--2.18 (m, 2H), 1.70 (d, *J* = 6.8 Hz, 3H), 1.42 (s, 9H), 0.65 (dd, *J* = 6.8, 7.2 Hz, 6H).

#### Alkylation {#sec4.1.17.2}

To a cooled (0 °C) solution of **S5** (24 mg, 0.03 mmol) in dry CH~2~Cl~2~ (2 mL, 0.02 M) was added dropwise BEMP (0.03 mL, 0.1 mmol). The resulting mixture was stirred at the same temperature for 10 min before tosylate **26** (39 mg, 0.1 mmol) in CH~2~Cl~2~ (1 mL, 0.1 M) was added. After stirring for 30 min at 0 °C, the reaction was quenched by addition of saturated aqueous NH~4~Cl, and the resulting mixture was extracted with CH~2~Cl~2~. The combined organic layers were washed with brine, dried over anhydrous Na~2~SO~4~, and concentrated *in vacuo*. The residue was purified by column chromatography (silica gel, hexanes/EtOAc, 2/1) to afford Boc-protected amine **29** (26 mg, 79%): ^1^H NMR (400 MHz, CDCl~3~) δ 8.15 (dd, *J* = 4.8, 8.4 Hz, 2H), 7.84--7.79 (m, 1H), 7.70 (s, 1H), 7.23 (d, *J* = 8.4 Hz, 2H), 6.87 (d, *J* = 8.4 Hz, 1H), 6.82--6.74 (m, 4H), 6.70--6.65 (m, 2H), 5.42--5.30 (m, 4H), 5.06 (br s, 1H), 4.23 (dd, *J* = 4.8, 4.8 Hz, 2H), 3.91--3.88 (m, 5H), 3.84 (s, 3H), 3.80 (s, 3H), 3.71 (dd, *J* = 4.4, 5.2 Hz, 2H), 3.63 (dd, *J* = 4.0, 4.8 Hz, 2H), 3.54 (dd, *J* = 4.8, 5.2 Hz, 2H), 3.31 (d, *J* = 4.8 Hz, 2H), 2.22--2.16 (m, 2H), 1.68 (dd, *J* = 6.8, 10.8 Hz, 6H), 1.41 (s, 9H), 0.63--0.59 (m, 6H).

### **MA14** {#sec4.1.18}

#### Boc Deprotection {#sec4.1.18.1}

To a cooled (0 °C) solution of **29** (26 mg, 0.03 mmol) in dry CH~2~Cl~2~ (1 mL, 0.03 M) was added dropwise TFA (0.5 mL). After stirring for 40 min at the same temperature, the solvent was removed under reduced pressure. The crude residue was employed in the next step without further purification;

#### Biotin Attachment {#sec4.1.18.2}

The residue was dissolved in dry DMF (1 mL, 0.03 M), and the mixture was treated with Et~3~N (0.009 mL, 0.06 mmol) followed by biotin *N*-hydroxysuccinimide ester (9 mg, 0.03 mmol) in DMF (1 mL, 0.03 M) at 0 °C. After stirring for 15 h at 25 °C, the reaction was quenched by addition of water, and the resulting mixture was extracted with CH~2~Cl~2~. The combined organic layers were washed with brine, dried over anhydrous Na~2~SO~4~, and concentrated *in vacuo*. The residue was purified by column chromatography (silica gel, CH~2~Cl~2~/MeOH, 10/1) to afford **MA14** as a colorless oil (28 mg, 99% for 2 steps): ^1^H NMR (400 MHz, CDCl~3~) δ 8.19--8.11 (m, 2H), 7.87--7.79 (m, 1H), 7.71 (s, 1H), 7.25--7.20 (m, 2H), 6.91--6.65 (m, 7H), 6.55 (br s, 1H), 5.69 (br s, 1H), 5.42--5.30 (m, 4H), 5.07--4.90 (m, 2H), 4.47--4.41 (m, 1H), 4.37--4.32 (m, 1H), 4.28--4.20 (m, 2H), 3.93--3.88 (m, 5H), 3.84 (s, 3H), 3.80 (s, 3H), 3.73--3.69 (m, 2H), 3.66--3.62 (m, 2H), 3.58--3.54 (m, 2H), 3.43--3.40 (m, 2H), 3.13--3.05 (m, 1H), 2.97--2.89 (m, 1H), 2.76--2.63 (m, 2H), 2.22--2.12 (m, 4H), 1.83--1.66 (m, 8H), 1.40--1.37 (m, 2H), 0.63--0.59 (m, 6H); IR (neat) 2162, 1506, 1148, 650 cm^--1^; HRMS (ESI) *m*/*z* 1120.4541 \[(M + H)^+^, C~57~H~68~F~3~N~5~O~13~S requires 1120.4559\].

Dual Luciferase-Reporter Assay {#sec4.2}
------------------------------

HEK-293T cells were seeded on 96-well plates at a density of 5 × 10^3^ cells/well and allowed to attach for 24 h. Cells were transfected with pGL3-5HRE-VEGF-luciferase plasmid containing five copies of HREs in human *VEGF* promoter and pRL-SV40 plasmid encoding *Renilla* luciferase using Vivamagic transfection reagent (Vivagene, Seongnam, Korea), according to the manufacturer's instructions. Cells were treated with hypoxic conditions (1% O~2~) and serially diluted compounds for 24 h after transfection. Luciferase reporter assay was performed using the Dual-Glo luciferase assay system (Promega, Madison, WI, USA) according to the manufacturer's instructions. Briefly, an equal volume of Dual-Glo reagent to culture medium was added to each well, and the mixture was incubated for 10 min. The firefly luminescence was measured using a microplate reader (Infinite M200 Pro, TECAN, Männedorf, Switzerland). Dual-Glo Stop & Glo reagent was added, and the mixture was incubated for 10 min before the measurement of *Renilla* luminescence. The firefly luminescence signals were normalized to the activity of *Renilla* luciferase. Three independent experiments were performed.

MTT Assay {#sec4.3}
---------

Cells were seeded on 96-well plates at a density of 1 × 10^4^ cells/well, and then incubated for 24 h. After cells were treated with various concentrations of compounds for 24 h under hypoxia, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, AMRESCO) solution was added to each well, and the mixture was incubated for another 4 h at 37 °C. The resulting formazan crystals were dissolved in DMSO (100 μL/well) and the absorbance of the plate was read with a microplate reader (Infinite M200 Pro, TECAN, Männedorf, Switzerland) at 540 nm. Three independent experiments were performed.

Western Blot Analysis {#sec4.4}
---------------------

Proteins were extracted from the cells using PRO--PREP (iNtRon Biotech, South Korea). Cell extracts were separated by SDS-PAGE and transferred to a nitrocellulose membrane (Whatman, Maidstone, England). The membranes were blocked with 5% skim milk in Tris-buffered saline (TBS) containing 0.1% Tween-20 for 30 min at room temperature. After blocking, membranes were incubated with specific primary antibodies overnight at 4 °C, followed by incubation with horseradish peroxidase-conjugated mouse- or rabbit-IgG for 1 h at room temperature. Membranes were then incubated with horseradish peroxidase-conjugated antibody mouse or rabbit immunoglobulins at room temperature and developed through West Pico chemiluminescent substrate (Pierce, Woburn, MA, USA).

RNA Isolation, Reverse Transcription--Polymerase Chain Reaction (RT-PCR) {#sec4.5}
------------------------------------------------------------------------

Total RNA was extracted from cells using TRIzoL Reagent (Invitrogen, Carlsbad, CA), and cDNA synthesis was performed using MMLV reverse transcriptase. Real-time PCR was performed using a SYBR Green PCR Master Mix (Applied Biosystems, CA, USA). Each PCR reaction contained cDNA with 10-fold dilution and gene-specific primers. The thermal cycle used was 2 min at 50 °C, 10 min at 95 °C, 40 cycles of 15 s denaturation at 95 °C with 1 min annealing at 60 °C. The mean cycle threshold (CT) values were calculated for the gene expression with normalization to β-actin as an internal control. Each experiment was performed in triplicate, and the average was calculated.
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